Pivotal Study for PSD502--The First Potential Treatment for Premature Ejaculation
Links shared publicly online about this topic.
- 1,591total visits
Pivotal Study for PSD502--The First Potential Treatment for Premature Ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc. today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
View full resource at newswise.com
Tags: Sexual Health, Pharma, Sex and Intimacy, Sexual Dysfunction
Most Recently Shared on November 19, 2009 at 2:58 pm By:
Pivotal Study for PSD502--The First Potential Treatment for Premature Ejaculation http://bit.ly/2EYeBD
Advertisement
